Log in
LON:EKF

Ekf Diagnostics Share Forecast, Price & News

GBX 56
+1.00 (+1.82 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
54.25
Now: GBX 56
58
50-Day Range
48.60
MA: GBX 54.15
59
52-Week Range
16.58
Now: GBX 56
60
Volume1.17 million shs
Average Volume1.10 million shs
Market Capitalization£254.57 million
P/E Ratio70.00
Dividend Yield1.82%
BetaN/A
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, and internationally. It offers DiaSpect Tm, an hemoglobin analyzer; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a centrifuge that provides a hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+, C-Line Clinic, and S-Line Lab+; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer for use in the determination of BHB in serum or plasma in ketosis patients. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; True20 and QuPID pregnancy tests for testing urine only or urine and serum; SensPoint, a lactate analyzer with docking station; and Lactate Scout+, a lactate analyzer. Further, the company offers Altair 240, an analyzer calibrated to run the Stanbio chemistry range of reagents; reagents, such as BHB for detecting ketosis, Procalcitonin for detecting sepsis, and glycated serum protein for use in the diagnosis and screening of diabetes; and contract manufacturing services, as well as services and distributes third party company products. It sells its products directly to GP surgeries, sports and diabetes clinics, blood banks, hospitals, laboratories, and government agencies, as well as through a network of distributors. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Read More
Ekf Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars


Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-29-20710570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£44.92 million
Cash FlowGBX 2.70 per share
Book ValueGBX 15.50 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£254.57 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 56
+1.00 (+1.82 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EKF News and Ratings via Email

Sign-up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ekf Diagnostics (LON:EKF) Frequently Asked Questions

How has Ekf Diagnostics' stock price been impacted by COVID-19 (Coronavirus)?

Ekf Diagnostics' stock was trading at GBX 26.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EKF stock has increased by 111.3% and is now trading at GBX 56.
View which stocks have been most impacted by COVID-19
.

How often does Ekf Diagnostics pay dividends? What is the dividend yield for Ekf Diagnostics?

Ekf Diagnostics announced a dividend on Tuesday, April 7th. Shareholders of record on Thursday, November 5th will be given a dividend of GBX 1 per share on Tuesday, December 1st. This represents a yield of 3.31%. The ex-dividend date of this dividend is Thursday, November 5th. The official announcement can be accessed at this link.
View Ekf Diagnostics' dividend history
.

Who are some of Ekf Diagnostics' key competitors?

What other stocks do shareholders of Ekf Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekf Diagnostics investors own include ERBA Diagnostics (ERBA), Kirkland Lake Gold (KLG), Telford Homes (TEF), ASOS (ASC), Advanced Computer Software Group (asw), Boohoo Group (BOO), Newmont Goldcorp (NEM), SolGold (SOLG), Arcontech Group (ARC) and Alliance Pharma (APH).

Who are Ekf Diagnostics' key executives?

Ekf Diagnostics' management team includes the following people:
  • Mr. Julian Huw Baines, CEO & Exec. Director (Age 54)
  • Mr. Richard Anthony Evans, COO, Fin. Director & Exec. Director (Age 62)
  • Mr. Andrew Webb, Chief Exec. Officer of Ekf Molecular
  • Salim Hamir, Company Sec.

What is Ekf Diagnostics' stock symbol?

Ekf Diagnostics trades on the London Stock Exchange (LON) under the ticker symbol "EKF."

How do I buy shares of Ekf Diagnostics?

Shares of EKF and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ekf Diagnostics' stock price today?

One share of EKF stock can currently be purchased for approximately GBX 56.

How big of a company is Ekf Diagnostics?

Ekf Diagnostics has a market capitalization of £254.57 million and generates £44.92 million in revenue each year.

What is Ekf Diagnostics' official website?

The official website for Ekf Diagnostics is www.ekfdiagnostics.com.

How can I contact Ekf Diagnostics?

Ekf Diagnostics' mailing address is Avon HSE, 19 Stanwell Road, PENARTH, CF64 2EZ, United Kingdom. The company can be reached via phone at +44-29-20710570.

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.